Clinical Trial Update: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ponatinib plus reduced-intensity chemotherapy as first-line therapy for adults with Philadelphia chromosome-positive acute lymphoblas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic | Conditions: Acute Lymphoblastic Leukemia, Adult, Ph+ ALL | Phase 2 | Status: TERMINATED